The Laura Chalk Rowles Lectureship in Dementia: Advances and Challenges in Frontotemporal Dementia
The Laura Chalk Rowles Lectureship in Dementia is organised by the Ï㽶ÊÓƵ Research Centre for Studies in Aging (MCSA)
To RSVP, please contactÌýalexandra.triantafillopoulos1 [at] mcgill.ca (Alexandra Triantafillopoulos)
Liyong Wu, MD, PhD
Professor and Deputy Director, Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
Dr. Liyong Wu is vice chief of the Department of Neurology at Xuanwu Hospital, Capital Medical University. He holds a doctoral supervisor position and is an Adjunct Professor at Ï㽶ÊÓƵ in Canada. He contributes as a member of the expert group for major chronic disease projects under China’s Ministry of Science and Technology (2016-2025). Dr. Wu’s primary research focuses on cognitive disorders such as frontotemporal dementia and tauopathies. He holds 12 national and provincial-level projects, including Principal Investigator for a key research and development project under the Ministry of Science and Technology. His research output includes 112 SCI articles published as corresponding authors in prestigious international journals such as JAMA Neurology, Brain, Annals of Neurology, JNNP, and others.
Dr. Wu established the first national multicenter FTD cohort in China, the CHIFGENS cohort, which ranks as China’s largest familial FTD registration network. His groundbreaking research into the pathogenic mechanisms of familial FTD in the Chinese population led to the discovery of novel gene mutation sites, elucidating the pathogenic gene functions, and identifying critical target genes for FTD's genetic mechanisms and drug development. Dr. Wu also pioneered a multidimensional early screening system for cognitive impairment in the elderly. Leveraging molecular imaging technologies, he has made significant strides in understanding FTD’s pathogenesis and early diagnostic biomarkers, providing robust scientific evidence for early diagnosis, disease monitoring, and selecting therapeutic targets. Moreover, he utilized optogenetic technology to explore the neural circuits underlying behavior of neural circuits in FTD. He also advanced novel therapeutic strategies, including mechanism-targeted treatments and neuroelectric modulation therapies for FTD.
